Статья
Сфинголипиды при ишемическом инсульте
Определение новых биомаркеров, участвующих в патогенезе ишемического инсульта, является чрезвычайно важной задачей с точки зрения определения возможных механизмов профилактики возникновения острого события, лучшей диагностики и воздействия на этапы патогенеза для разрешения воспаления. Сфинголипиды относят к новым биомаркерам атеросклероза, которые участвуют в воспалении, апоптозе и ишемии. Широкое внедрение масс-спектрометрии позволило изучать их более детально. Целью настоящего обзора является обобщение имеющихся данных о роли сфинголипидов при ишемическом инсульте.
1. Pettus B.J., Chalfant C.E., Hannun Y.A. Ceramide in apoptosis: an overview and current perspectives. Biochim. Biophys. Acta, 2002; 1585 (2-3): 114–125. doi:10.1016/s1388-1981(02)00331-1
2. Mohamud Y.A., Hagemann N., Hermann D.M. The acid sphingomyelinase/ceramide system as target for ischemic stroke therapies. Neurosignals, 2019; 27 (S1): 32–43. doi:10.33594/000000184
3. Алесенко А.В., Затейщиков Д.А., Лебедев А.Т., Курочкин И.Н. Участие сфинголипидов в патогенезе атеросклероза. Кардиология, 2019; 59 (8): 77–87.
4. Hannun Y.A., Obeid L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature reviews. Mol. Cell Biol., 2008; 9 (2): 139–150. doi:10.1038/nrm2329
5. Manicke N.E., Nefliu M., Wu C., Woods J.W., Reiser V., Hendrickson R.C., Cooks R.G. Imaging of lipids in atheroma by desorption electrospray ionization mass spectrometry. Anal. Chem., 2009; 81 (21): 8702–8707. doi:10.1021/ac901739s
6. Brunkhorst R., Friedlaender F., Ferreirós N., Schwalm S., Koch A., Grammatikos G., Toennes S., Foerch C., Pfeilschifter J., Pfeilschifter W. Alterations of the ceramide metabolism in the peri-infarct cortex are independent of the sphingomyelinase pathway and not influenced by the acid sphingomyelinase inhibitor fluoxetine. Neural Plasticity, 2015; 2015: 503079. doi:10.1155/2015/503079
7. Abe T., Niizuma K., Kanoke A., Saigusa D., Saito R., Uruno A., Fujimura M., Yamamoto M., Tominaga T. Metabolomic analysis of mouse brain after a transient middle cerebral artery occlusion by mass spectrometry imaging. Neurol. Medico-Chirur., 2018; 58 (9): 384–392. doi:10.2176/nmc.oa.2018-0054
8. Henderson F., Hart P.J., Pradillo J.M., Kassiou M., Christie L., Williams K.J., Boutin H., McMahon A. Multi-modal imaging of long-term recovery poststroke by positron emission tomography and matrixassisted laser desorption/ionisation mass spectrometry. Rapid Commun. Mass Spectrom., 2018; 32 (9): 721–729. doi:10.1002/rcm.8090
9. Nielsen M.M., Lambertsen K.L., Clausen B.H., Meyer M., Bhandari D.R., Larsen S.T., Poulsen S.S., Spengler B., Janfelt C., Hansen H.S. Mass spectrometry imaging of biomarker lipids for phagocytosis and signalling during focal cerebral ischaemia. Sci. Rep., 2016; 6: 39571. doi:10.1038/srep39571
10. Le Stunff H., Milstien S., Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J. Cell. Biochem., 2004; 92 (5): 882–899. doi:10.1002/jcb.20097
11. Urtz N., Gaertner F., von Bruehl M.L., Chandraratne S., Rahimi F., Zhang L., Orban M., Barocke V., Beil J., Schubert I., Lorenz M., Legate K.R., Huwiler A., Pfeilschifter J.M., Beerli C., Ledieu D., Persohn E., Billich A., Baumruker T., Mederos y Schnitzler M., Massberg S. Sphingosine 1-phosphate produced by sphingosine kinase 2 intrinsically controls platelet aggregation in vitro and in vivo. Circ. Res., 2015; 117 (4): 376–387. doi:10.1161/circresaha.115.306901
12. Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim. Biophys. Acta, 2002; 1582 (1-3): 132–137. doi:10.1016/s1388-1981(02)00147-6
13. Kurano M., Yatomi Y. Sphingosine 1-phosphate and atherosclerosis. J. Atheroscler. Thromb., 2018; 25 (1): 16–26. doi:10.5551/jat.RV17010
14. Kimura T., Sato K., Malchinkhuu E., Tomura H., Tamama K., Kuwabara A., Murakami M., Okajima F. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol., 2003; 23 (7): 1283–1288. doi:10.1161/01.atv.0000079011.67194.5a
15. Nofer J.R., van der Giet M., Tölle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., Tietge U.J., Gödecke A., Ishii I., Kleuser B., Schäfers M., Fobker M., Zidek W., Assmann G., Chun J., Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest., 2004; 113 (4): 569–581. doi:10.1172/jci18004
16. Kimura T., Tomura H., Mogi C., Kuwabara A., Damirin A., Ishizuka T., Sekiguchi A., Ishiwara M., Im D.S., Sato K., Murakami M., Okajima F. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoproteininduced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem., 2006; 281 (49): 37457–37467. doi:10.1074/jbc.M605823200
17. Ruiz M., Frej C., Holmer A., Guo L.J., Tran S., Dahlback B. High-density lipoprotein-associated apolipoprotein m limits endothelial inflammation by delivering sphingosine-1-phosphate to the sphingosine-1-phosphate receptor 1. Arterioscler. Thromb. Vasc. Biol, 2017; 37 (1): 118–129. doi:10.1161/ATVBAHA.116.308435
18. Tamama K., Tomura H., Sato K., Malchinkhuu E., Damirin A., Kimura T., Kuwabara A., Murakami M., Okajima F. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis, 2005; 178 (1): 19–23. doi:10.1016/j.atherosclerosis.2004.07.032
19. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., Allende M.L., Proia R.L., Cyster J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature, 2004; 427 (6972): 355–360. doi:10.1038/nature02284
20. Drouillard A., Neyra A., Mathieu A.L., Marçais A., Wencker M., Marvel J., Belot A., Walzer T. Human naive and memory T cells display opposite migratory responses to sphingosine-1 phosphate. J. Immunol, 2018; 200 (2): 551–557. doi:10.4049/jimmunol.1701278
21. Lucaciu A., Kuhn H., Trautmann S., Ferreirós N., Steinmetz H., Pfeilschifter J., Brunkhorst R., Pfeilschifter W., Subburayalu J., Vutukuri R. A Sphingosine 1-phosphate gradient is linked to the cerebral recruitment of T helper and regulatory T helper cells during acute ischemic stroke. Int. J. Mol. Sci., 2020; 21 (17). doi:10.3390/ijms21176242
22. Cao R., Li J., Kharel Y., Zhang C., Morris E., Santos W.L., Lynch K.R., Zuo Z., Hu S. Photoacoustic microscopy reveals the hemodynamic basis of sphingosine 1-phosphate-induced neuroprotection against ischemic stroke. Theranostics, 2018; 8 (22): 6111–6120. doi:10.7150/thno.29435
23. Bojic L.A., McLaren D.G., Shah V., Previs S.F., Johns D.G., Castro-Perez J.M. Lipidome of atherosclerotic plaques from hypercholesterolemic rabbits. Int. J. Mol. Sci., 2014; 15 (12): 23283–23293. doi:10.3390/ijms151223283
24. Vorkas P.A., Shalhoub J., Lewis M.R., Spagou K., Want E.J., Nicholson J.K., Davies A.H., Holmes E. Metabolic phenotypes of carotid atherosclerotic plaques relate to stroke risk: an exploratory study. Eur. J. Vasc. Endovasc. Surg., 2016; 52 (1): 5–10. doi:10.1016/j.ejvs.2016.01.022
25. Edsfeldt A., Dunér P., Ståhlman M., Mollet I.G., Asciutto G., Grufman H., Nitulescu M., Persson A.F., Fisher R.M., Melander O., Orho-Melander M., Borén J., Nilsson J., Gonçalves I. Sphingolipids contribute to human atherosclerotic plaque inflammation. Arterioscler. Thromb. Vasc. Biol., 2016; 36 (6): 1132– 1140. doi:10.1161/atvbaha.116.305675
26. Testai F.D., Hillmann M., Amin-Hanjani S., Gorshkova I., Berdyshev E., Gorelick P.B., Dawson G. Changes in the cerebrospinal fluid ceramide profile after subarachnoid hemorrhage. Stroke, 2012; 43 (8): 2066–2070. doi:10.1161/strokeaha.112.650390
27. Fiedorowicz A., Kozak-Sykała A., Bobak Ł., Kałas W., Strządała L. Ceramides and sphingosine-1-phosphate as potential markers in diagnosis of ischaemic stroke. Neurologia i neurochirurgia polska, 2019; 53 (6): 484– 491. doi:10.5603/PJNNS.a2019.0063
28. Gui Y.K., Li Q., Liu L., Zeng P., Ren R.F., Guo Z.F., Wang G.H., Song J.G., Zhang P. Plasma levels of ceramides relate to ischemic stroke risk and clinical severity. Brain Res. Bull., 2020; 158: 122–127. doi:10.1016/j.brainresbull.2020.03.009
29. Chao H.C., Lee T.H., Chiang C.S., Yang S.Y., Kuo C.H., Tang S.C. Sphingolipidomics investigation of the temporal dynamics after ischemic brain injury. J. Proteome Res., 2019; 18 (9): 3470–3478. doi:10.1021/acs.jproteome.9b00370
30. Guo X., Li Z., Zhou Y., Yu S., Yang H., Zheng L., Liu Y., Sun Y. Metabolic profile for prediction of ischemic stroke in chinese hypertensive population. J. Stroke Cerebrovasc. Dis., 2019; 28 (4): 1062–1069. doi:10.1016/j.jstrokecerebrovasdis.2018.12.035
31. Lind L., Salihovic S., Ganna A., Sundstrom J., Broeckling C.D., Magnusson P.K., Pedersen N.L., Siegbahn A., Prenni J., Fall T., Ingelsson E., Arnlov J. A Multi-cohort metabolomics analysis discloses sphingomyelin (32:1) levels to be inversely related to incident ischemic stroke. J. Stroke Cerebrovasc., Dis., 2020; 29 (2): 104476. doi:10.1016/j.jstrokecerebrovasdis.2019.104476